- ๐ฎ๐ช Blog ActionCovid1984.org
- ๐ฎ๐ช Irish Examiner
- Inverse
- ๐ฎ๐ช Gript media
- Blake-Lemoine - LaMBDA
- ๐ฎ๐ช Over Dee Wall
- The Defender News
- ๐ฎ๐ช BreakingNews.ie
- Dr Vernon Coleman
- Rebel News
- Vaccine Choice Canada NEWS
- SHFT Plan
- The Expose
- ๐ฎ๐ช Robert Pierzyลski PJ
- ๐ฎ๐ช Noiz TV
- ๐ฎ๐ช Media Hub Ireland
- ๐ฎ๐ช The Irish Inquiry
- ๐ฎ๐ช Liberty Stream Net Ireland
- ๐ฎ๐ช GriptMedia
- ๐ฎ๐ช WeThePeople.ie
- ๐ฎ๐ช Action-Covid-1984
- ๐ฎ๐ช Lets wake up our Capital
- ๐ฎ๐ช Peter Madden
- ๐ฎ๐ช Lets Wake Up Call!!!
- WW Freedom Rallies
- Piers Corbyn
- ๐ฎ๐ช Tracey OMahony
What's new
What's new
EU/HMA Big Data Stakeholder Forum 2022, from 01/12/2022 to 01/12/2022
EU/HMA Big Data Stakeholder Forum 2022, from 01/12/2022 to 01/12/2022
25 November 2022
Human medicines European public assessment report (EPAR): Remsima, infliximab, Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Psoriasis;Crohn Disease;Arthritis, Rheumatoid, Date of authorisation: 10/09/2013, Revision: 30, Status: Authorised
Human medicines European public assessment report (EPAR): Remsima, infliximab, Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Psoriasis;Crohn Disease;Arthritis, Rheumatoid, Date of authorisation: 10/09/2013, Revision: 30, Status: Authorised
25 November 2022
Human medicines European public assessment report (EPAR): Revlimid, lenalidomide, Multiple Myeloma;Lymphoma, Mantle-Cell;Myelodysplastic Syndromes, Date of authorisation: 14/06/2007, Revision: 47, Status: Authorised
Human medicines European public assessment report (EPAR): Revlimid, lenalidomide, Multiple Myeloma;Lymphoma, Mantle-Cell;Myelodysplastic Syndromes, Date of authorisation: 14/06/2007, Revision: 47, Status: Authorised
25 November 2022
Human medicines European public assessment report (EPAR): Rubraca, rucaparib, Ovarian Neoplasms, Date of authorisation: 23/05/2018, Revision: 10, Status: Authorised
Human medicines European public assessment report (EPAR): Rubraca, rucaparib, Ovarian Neoplasms, Date of authorisation: 23/05/2018, Revision: 10, Status: Authorised
25 November 2022
Human medicines European public assessment report (EPAR): Multaq, dronedarone, Atrial Fibrillation, Date of authorisation: 25/11/2009, Revision: 18, Status: Authorised
Human medicines European public assessment report (EPAR): Multaq, dronedarone, Atrial Fibrillation, Date of authorisation: 25/11/2009, Revision: 18, Status: Authorised
25 November 2022
Human medicines European public assessment report (EPAR): Comirnaty, tozinameran,riltozinameran and tozinameran,famtozinameran and tozinameran,COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 virus infection, Date of authorisation: 21/12/2020, Revision: 34, Status: Authorised
Human medicines European public assessment report (EPAR): Comirnaty, tozinameran,riltozinameran and tozinameran,famtozinameran and tozinameran,COVID-19 mRNA Vaccine (nucleoside modified), COVID-19 virus infection, Date of authorisation: 21/12/2020, Revision: 34, Status: Authorised
25 November 2022
Human medicines European public assessment report (EPAR): Tasmar, tolcapone, Parkinson Disease, Date of authorisation: 27/08/1997, Revision: 24, Status: Authorised
Human medicines European public assessment report (EPAR): Tasmar, tolcapone, Parkinson Disease, Date of authorisation: 27/08/1997, Revision: 24, Status: Authorised
25 November 2022
Human medicines European public assessment report (EPAR): Tavneos, avacopan, Microscopic Polyangiitis;Wegener Granulomatosis, Date of authorisation: 11/01/2022, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Tavneos, avacopan, Microscopic Polyangiitis;Wegener Granulomatosis, Date of authorisation: 11/01/2022, Revision: 1, Status: Authorised
25 November 2022
Human medicines European public assessment report (EPAR): Melatonin Neurim, melatonin, Sleep Initiation and Maintenance Disorders, Date of authorisation: 07/11/2022, Status: Authorised
Human medicines European public assessment report (EPAR): Melatonin Neurim, melatonin, Sleep Initiation and Maintenance Disorders, Date of authorisation: 07/11/2022, Status: Authorised
25 November 2022
Dorzolamide : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003168/202202
Dorzolamide : CMDh Scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation - PSUSA/00003168/202202
25 November 2022